Anti-VEGF Gains Ground in PDR - Scorecard - MDSpire

Anti-VEGF Gains Ground in PDR

Brolucizumab challenges laser procedure in proliferative diabetic retinopathy management

  • May 28, 2026

  • 4 min

Share

Clinical Scorecard: Anti-VEGF Gains Ground in PDR

At a Glance

CategoryDetail
ConditionProliferative Diabetic Retinopathy (PDR)
Key MechanismsAnti-VEGF therapy with brolucizumab vs. panretinal photocoagulation (PRP)
Target PopulationTreatment-naïve patients with PDR
Care SettingClinical trial across multiple sites

Key Highlights

  • Brolucizumab showed a mean gain of 0.2 letters in BCVA compared to a decline of 4.2 letters with PRP.
  • 63.6% of brolucizumab patients had no evidence of PDR at week 54 vs. 22.4% with PRP.
  • Lower rates of CI-DME were observed with brolucizumab (31.1% vs 72.7%).
  • Overall ocular adverse events were less frequent in the brolucizumab group (34.3% vs 49.1% with PRP).

Guideline-Based Recommendations

Diagnosis

  • Assess visual acuity and disease status in patients with PDR.

Management

    Monitoring & Follow-up

    • Monitor for intraocular inflammation and other ocular adverse events in patients receiving brolucizumab.

    Risks

    • Be aware of potential adverse events including retinal vasculitis with brolucizumab.

    Patient & Prescribing Data

    Treatment-naïve patients with PDR

    Clinical Best Practices

      Related Resources & Content

      Original Source(s)

      Anti-VEGF Gains Ground in PDR

      • May 28, 2026

      Related Content

      Myopia Management: Treat the Growing Eye, Not Just the Prescription

      When to start, what to measure, how to monitor, and when to adjust course

      Accelerating Peer Learning in Eye Care

      Lumenis launches peer-to-peer learning program aimed at developing practical strategies for modern-day practice

      • May 27, 2026

      • 2 min
      Retinal Age as Disease Biomarker

      Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

      • May 27, 2026

      • 3 min